Essentials from the 2015 European <scp>AIDS</scp> Clinical Society (<scp>EACS</scp>) guidelines for the treatment of adult <scp>HIV</scp>‐positive persons

Ryom, Lene; Boesecke, Christoph; Gisler, Valentin; Manzardo, Christian; Rockstroh, Jürgen K.; Puoti, Massimo; Furrer, Hansjakob; Miró, JM; Gatell, José M.; Pozniak, Anton; Behrens, Georg; Battegay, Manuel; Lundgren, JD

doi:10.1111/hiv.12322

Cited by 88 publications

(67 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding clinical management of HTA, age, ethnicity and the presence of comorbidities such as renal impairment, diabetes, heart failure and ischemic heart disease together with potential drug-drug interactions should guide the selection of the antihypertensive therapy [119]. …”

Section: Discussionmentioning

confidence: 99%

Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV

et al. 2016

View full text Add to dashboard Cite

With widespread and effective antiretroviral therapy, the life expectancy in the HIV population has dramatically improved over the last two decades. Consequently, as patients are aging with HIV, other age-related comorbidities, such as metabolic disturbances and cardiovascular disease (CVD), have emerged as important causes of morbidity and mortality. An overrepresentation of traditional cardiovascular risk factors (RF), toxicities associated with long exposure to antiretroviral therapy, together with residual chronic inflammation and immune activation associated with HIV infection are thought to predispose to these metabolic complications and to the excess risk of CVD observed in the HIV population. The metabolic syndrome (MS) represents a clustering of RF for CVD that includes abdominal obesity, hypertension, dyslipidemia, and insulin resistance. Hypertension is a prevalent feature of the MS in HIV, in particular in the aging population, and constitutes an important RF for CVD. Physicians should screen their patients for metabolic and cardiovascular risk at the regular visits to reduce MS and the associated CVD risk among people aging with HIV, since many of RF are under-diagnosed and under-treated conditions. Interventions to reduce these RF can include life-style changes and pharmacological interventions such as antihypertensive and lipid-lowering therapy, and treatment of glucose metabolism disturbances. Changes in antiretroviral therapy to more metabolic neutral antiretroviral drugs may also be considered.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Cardiovascular disease, bone, metabolic and renal diseases have received much attention, and specific recommendations for prevention are available for these conditions 1. COPD is a world-leading cause of life years lost in the general population,2 and is associated with modifiable risk factors 3.…”

Section: Introductionmentioning

confidence: 99%

Airflow limitation in people living with HIV and matched uninfected controls

Ronit

Lundgren

Afzal

et al. 2018

Thorax

View full text Add to dashboard Cite

show abstract

“…Boosted darunavir is the preferred protease inhibitor (PI) for antiretroviral treatment (ART)-naïve patients that is recommended by most HIV guidelines worldwide 1,2. The efficacy of darunavir/ritonavir 800/100 mg once-daily formulation has been proved in many clinical trials in patients starting ART 3.…”

Section: Introductionmentioning

confidence: 99%

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS

Navarro¹,

Curran²

2016

HIV

View full text Add to dashboard Cite

Efficacy is the main objective of antiretroviral treatment and adherence is one of the cornerstones to achieve it. For this reason, treatment simplification is of key importance with regard to antiretroviral regimens. Rezolsta® (darunavir/cobicistat) is the first fixed-dose combination containing a protease inhibitor approved for HIV treatment. This coformulation includes darunavir, a protease inhibitor that has shown its efficacy and safety in naïve and treatment-experienced patients, and cobicistat, the new pharmacokinetic enhancer that is expected to replace ritonavir. Bioequivalence between ritonavir and cobicistat as darunavir boosters has been shown in studies involving healthy volunteers. Furthermore, efficacy and safety of darunavir/cobicistat observed in phase III studies, including naïve and pretreated patients without darunavir-associated resistance mutations, are comparable to historical data of darunavir/ritonavir 800/100 mg once-daily formulation. Adverse events with darunavir/cobicistat are scarce and mild, and basically include skin reactions and gastrointestinal disturbances. Although small increases in plasma creatinine are expected in patients receiving cobicistat due to the inhibition of creatinine transporters in kidney tubules, actual glomerular filtrate rate remains unaltered. Cobicistat does not have an inducer effect on metabolic pathways and shows much more selective inhibition than ritonavir. Therefore, isoenzyms different from CYP3A4 are supposed to be less affected by cobicistat, and thus fewer drug–drug interactions are expected.

show abstract

Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV‐positive persons

Cited by 88 publications

References 0 publications

Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV

Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV

Airflow limitation in people living with HIV and matched uninfected controls

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS

Contact Info

Product

Resources

About